pocketful logo
Vasundhara Rasayans Ltd logo

Vasundhara Rasayans Ltd

NSE: BSE: 538634

105.65

(-1.86%)

Wed, 08 Apr 2026, 10:11 pm

Vasundhara Rasayans Analysis

dividend

thumbs up icon

Pros

  • Dividends paid are well covered by earnings (4.4x coverage).
  • Vasundhara Rasayans's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
thumbs up icon

Cons

  • Dividend payments have increased, but Vasundhara Rasayans only paid a dividend in the past 5 years.
  • Vasundhara Rasayans has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Vasundhara Rasayans's dividend is below the markets top 25% of dividend payers in India (3.08%).

health

thumbs up icon

Pros

  • Vasundhara Rasayans is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vasundhara Rasayans is profitable, therefore cash runway is not a concern.
  • Vasundhara Rasayans is profitable, therefore cash runway is not a concern.
  • Debt is well covered by operating cash flow (174.4%, greater than 20% of total debt).
  • Debt is covered by short term assets, assets are 94.3x debt.
  • Vasundhara Rasayans's cash and other short term assets cover its long term commitments.
  • The level of debt compared to net worth has been reduced over the past 5 years (77.8% vs 1.5% today).
  • Vasundhara Rasayans earns more interest than it pays, coverage of interest payments is not a concern.
  • Vasundhara Rasayans's level of debt (1.5%) compared to net worth is satisfactory (less than 40%).
  • Low level of unsold assets.
thumbs up icon

Cons

    management

    thumbs up icon

    Pros

    • The tenure for the Vasundhara Rasayans board of directors is about average.
    • Rajesh's remuneration is lower than average for companies of similar size in India.
    • The average tenure for the Vasundhara Rasayans management team is over 5 years, this suggests they are a seasoned and experienced team.
    thumbs up icon

    Cons

    • Rajesh's compensation has increased by more than 20% in the past year whilst earnings grew less than 20%.

    misc

    thumbs up icon

    Pros

      thumbs up icon

      Cons

      • Vasundhara Rasayans is not covered by any analysts.
      • Vasundhara Rasayans has significant price volatility in the past 3 months.

      past

      thumbs up icon

      Pros

      • Vasundhara Rasayans's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
      thumbs up icon

      Cons

      • Vasundhara Rasayans's 1-year earnings growth is less than its 5-year average (10% vs 14.8%)
      • Vasundhara Rasayans used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
      • Vasundhara Rasayans's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
      • Vasundhara Rasayans has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
      • Vasundhara Rasayans's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (10% vs 22.7%).

      value

      thumbs up icon

      Pros

      • Vasundhara Rasayans is good value based on assets compared to the IN Pharmaceuticals industry average.
      • Vasundhara Rasayans is good value based on earnings compared to the IN Pharmaceuticals industry average.
      • Vasundhara Rasayans is good value based on earnings compared to the India market.
      • 538634 outperformed the Market in India which returned -14.5% over the past year.
      • BSE:538634 is up 6.8% along with the Pharmaceuticals industry (6.8%) over the past month.
      thumbs up icon

      Cons

      • Vasundhara Rasayans's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
      • Vasundhara Rasayans's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
      • 538634 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
      • BSE:538634 is up 6.8% underperforming the market in India which returned 8% over the past month.

      Open Your Free Demat Account Now!

      Step into a world of zero fees and limitless opportunities!

      pocketful logo

      2022-25 Pocketful. All rights reserved, Built with in India

      Version -5.76

      app image 1app image 2

      Explore

      Calculatorsfooter arrow down icon
      Popular Calculatorsfooter arrow down icon
      Group Stocksfooter arrow down icon

      Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800